TY - JOUR
T1 - [18F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva
T2 - From Molecular Mechanisms to Clinical Applications in Bone Disorders
AU - Zwama, Jolien
AU - Rosenberg, Neeltje M.
AU - Verheij, Vincent A.
AU - Raijmakers, Pieter G. H. M.
AU - Yaqub, Maqsood
AU - Botman, Esmée
AU - de Ruiter, Ruben D.
AU - Garrelfs, Mark R.
AU - Bökenkamp, Arend
AU - Micha, Dimitra
AU - Schwarte, Lothar A.
AU - Teunissen, Bernd P.
AU - Lammertsma, Adriaan A.
AU - Boellaard, Ronald
AU - Eekhoff, Elisabeth M. W.
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/10/1
Y1 - 2024/10/1
N2 - Fibrodysplasia ossificans progressiva (FOP) is a rare genetic bone disorder characterized by episodic flare-ups in connective tissue, which are frequently followed by the formation of heterotopic ossification. The absence of available plasma-soluble biomarkers for flare-ups or heterotopic bone formation poses severe challenges to the monitoring of disease activity to measure or predict disease progression. Recently, 18-fluor-sodium fluoride positron emission tomography/computed tomography ([18F]NaF PET/CT) was introduced as a potential marker for ossifying FOP activity. This review discusses the pharmacokinetics of [18F]NaF in relation to the pathophysiology of FOP, and its use as a marker of local bone metabolism in a variety of bone-related disorders. In addition, the review specifically addresses the applicability of [18F]NaF PET/CT imaging in FOP as a monitoring modality.
AB - Fibrodysplasia ossificans progressiva (FOP) is a rare genetic bone disorder characterized by episodic flare-ups in connective tissue, which are frequently followed by the formation of heterotopic ossification. The absence of available plasma-soluble biomarkers for flare-ups or heterotopic bone formation poses severe challenges to the monitoring of disease activity to measure or predict disease progression. Recently, 18-fluor-sodium fluoride positron emission tomography/computed tomography ([18F]NaF PET/CT) was introduced as a potential marker for ossifying FOP activity. This review discusses the pharmacokinetics of [18F]NaF in relation to the pathophysiology of FOP, and its use as a marker of local bone metabolism in a variety of bone-related disorders. In addition, the review specifically addresses the applicability of [18F]NaF PET/CT imaging in FOP as a monitoring modality.
KW - F-sodium fluoride (F-NaF)
KW - fibrodysplasia ossificans progressiva
KW - heterotopic ossification
KW - musculoskeletal development
KW - osteoblasts
KW - positron emission tomography/computed tomography (PET/CT)
KW - rare bone diseases
UR - https://www.scopus.com/pages/publications/85207679333
U2 - 10.3390/biom14101276
DO - 10.3390/biom14101276
M3 - Review article
C2 - 39456213
SN - 2218-273X
VL - 14
JO - Biomolecules
JF - Biomolecules
IS - 10
M1 - 1276
ER -